IREN Posts 11% Bounce But Short Interest Holds at 34.5% Into Earnings

IREN recovered 11% on Tuesday to close at $24.46, but the week still left shareholders down nearly 11% and the month down 41%, while short sellers, holding 34.5% of the free float, the heaviest position in ORTEX's daily estimate series for this stock, barely flinched.

The positioning picture has not materially shifted from last week's note. Short interest eased just 1.2% over the past week to 97.7 million shares, a rounding error against the 25% build seen across October. Availability tightened further to 2.2%, down from 3.2% a week ago and down from levels above 20% in late September: at current readings, fewer than one in forty-five shares in the lending pool remains unborrowed. The 52-week low hit 0.35%, so there is room to tighten further, and the direction has been consistently downward for six weeks. Cost to borrow dropped 19% over the week to 0.70%, its lowest point in the data window. Cheap carry combined with near-zero availability describes a short base that is dug in, not one reacting to daily price moves. The ORTEX short score of 68.8, placing IREN in the sixth percentile of all stocks on the pressure ranking, has barely moved over the past ten sessions, reinforcing that the structural short thesis has not changed. Options, however, are now tilting modestly the other way. The put/call ratio rose to 0.73 on Tuesday, 1.8 standard deviations above its 20-day mean of 0.68, a notable shift from the call-skewed reading of 0.65 flagged in both earlier notes this month. The PCR is still well below its 52-week high of 1.08, but the direction of travel is toward more defensive positioning heading into Wednesday's earnings release.

The Street is split on valuation but leans bullish on direction. B. Riley trimmed its target from $91 to $64 on October 30, maintaining its Buy rating, continuing a series of downward revisions that have brought the firm's view in from $96 two months ago. JP Morgan upgraded IREN to Overweight in September with a $65 target, a meaningful signal given the firm's prior Underweight stance. Rothschild initiated at Neutral with a $40 target in late September, the most sceptical recent call. The consensus mean sits at $75.42 against Tuesday's close of $24.46, a gap that reflects genuine disagreement about timing rather than direction. The bull case rests on the vertically integrated model: over 5GW of potential power capacity, roughly $730MW of compute expected next year, a 2026 ARR target of around $4 billion, and GPU contract values that have risen approximately 125% since November 2024. The bear case focuses on execution risk at Sweetwater, the $25 to $30 billion FY27 capex guide, and roughly $3 to $8 billion of funding still unresolved, with data centre and GPU costs expected to rise 15% or more.

The index rebalance radar adds a mechanical dimension that neither bulls nor bears can vote around. ORTEX puts the probability of IREN leaving the MSCI World and MSCI USA indices at 97% at the November 2026 Quarterly Review, with an announcement expected November 11 and a trade date of November 30. That implies roughly $675 million of forced selling from MSCI World trackers and $377 million from MSCI USA trackers, combined, over $1 billion of index-driven supply landing in the final week of November. The stock is trading 37.1% below the exit threshold of $33.52, so the deletion is effectively decided at current prices. At the same time, ORTEX forecasts addition to MSCI World Small and MSCI USA Small with the same 97% probability, which would bring $672 million and $377 million of buying from smaller-cap trackers on the same trade date. The net flow depends on which tracker community is larger, but the gross volume, roughly 0.6 days of average daily volume for the World rebalance alone, is not trivial for a stock whose lending pool is already near-fully absorbed.

The peer group bounced hard on Tuesday. RIOT gained 18.4%, CIFR 18.4%, HUT 15.9%, KEEL 15.9%, CLSK 14.0%, WULF 14.5%, and CORZ 13.9%. IREN's 11% move on the day was the softest in the group, consistent with its recent pattern of underperforming peers: down 41% over the past month against a peer median of around 35%, and down more than 10% over the week against a peer median decline of roughly 2%. The heavier short load on IREN relative to any peer is part of that drag, though the daily price move suggests some short covering accompanied Tuesday's bounce.

The earnings print, scheduled for November 5, is the immediate test. IREN's two most recent quarterly results produced next-day declines of 8.4% and 10.4% respectively, though both recovered to positive territory within five sessions. With short interest at 34.5% of float, availability at 2.2%, a forced MSCI rebalance expected on November 30, and the PCR now rising above its recent range, the November 11 MSCI announcement is the next concrete date to watch alongside Wednesday's figures.